116 related articles for article (PubMed ID: 12451286)
21. Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.
Würthwein G; Krümpelmann S; Tillmann B; Real E; Schulze-Westhoff P; Jürgens H; Boos J
Anticancer Drugs; 1999 Oct; 10(9):807-14. PubMed ID: 10587290
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
23. Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations.
Jaehde U
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):76-8. PubMed ID: 9147713
[No Abstract] [Full Text] [Related]
24. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of total and unbound etoposide.
Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
[TBL] [Abstract][Full Text] [Related]
26. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
27. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
28. A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children.
Lowis SP; Price L; Pearson AD; Newell DR; Cole M
Br J Cancer; 1998 Jun; 77(12):2318-23. PubMed ID: 9649152
[TBL] [Abstract][Full Text] [Related]
29. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
[TBL] [Abstract][Full Text] [Related]
30. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
Hande K; Messenger M; Wagner J; Krozely M; Kaul S
Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
32. Effect of grapefruit juice intake on etoposide bioavailability.
Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
[TBL] [Abstract][Full Text] [Related]
33. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
[TBL] [Abstract][Full Text] [Related]
34. [Level of evidence for therapeutic drug monitoring for etoposide after oral administration].
Schieveen PG; Hulin A; Muret P; Royer B;
Therapie; 2010; 65(3):207-12. PubMed ID: 20699072
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
[TBL] [Abstract][Full Text] [Related]
36. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
Reif S; Kingreen D; Kloft C; Grimm J; Siegert W; Schunack W; Jaehde U
Cancer Chemother Pharmacol; 2001 Aug; 48(2):134-40. PubMed ID: 11561779
[TBL] [Abstract][Full Text] [Related]
37. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
38. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives.
Aguilar Ponce JL; Flores-Picazo Y; Pérez-Urizar J; Castañeda-Hernández G; Zinser-Sierra JW; Dueñas-González A; Calderón-Flores E; Segura-Pacheco BA; de la Garza-Salazar J
Arch Med Res; 1999; 30(3):212-5. PubMed ID: 10427872
[TBL] [Abstract][Full Text] [Related]
39. Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study.
Yang HZ; Liu L; Xu X
Arzneimittelforschung; 2012 Dec; 62(12):661-5. PubMed ID: 23192689
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
Joel SP; Ellis P; O'Byrne K; Papamichael D; Hall M; Penson R; Nicholls S; O'Donnell C; Constantinou A; Woodhull J; Nicholson M; Smith I; Talbot D; Slevin M
J Clin Oncol; 1996 Jun; 14(6):1903-12. PubMed ID: 8656259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]